Widespread Acceptance and Use of Accuray's Technologies Continue to Grow

   Widespread Acceptance and Use of Accuray's Technologies Continue to Grow

More than 700 CyberKnife® and TomoTherapy® Systems Have Treated More Than Half
a Million Patients Worldwide

PR Newswire

SUNNYVALE, Calif., Nov. 25, 2013

SUNNYVALE, Calif., Nov. 25, 2013 /PRNewswire/ --Accuray Incorporated (Nasdaq:
ARAY) announced today continued momentum in global adoption of its CyberKnife®
and TomoTherapy® Systems. Accuray has expanded its installed base to more than
700 systems worldwide which have been used to treat more than half a million
patients, further positioning the company as a leader in precise, innovative
radiation oncology. To date, the CyberKnife and TomoTherapy Systems have been
used in 40 countries to treat patients across the full spectrum of radiation
oncology cases including prostate, lung, liver, breast and head and neck

"The CyberKnife and TomoTherapy Systems are widely recognized by the global
oncology community as leading edge, innovative treatment solutions," said
Joshua H. Levine, president and chief executive officer of Accuray. "These
installation and patient milestones reflect our Systems' continued and growing
adoption across the world. Though we are proud of these achievements, there
are many more patients that could benefit from the personalized, non-invasive
treatment options our technologies provide. We will continue our commitment to
maximizing patient access and coverage, while working toward a future where
the fear, pain and suffering of cancer are a thing of the past."

"With the ability to image my patients every day I can create highly conformal
treatment plans that are more specific to the tumor and can be delivered in
fewer doses, thusallowing me to treat indications ranging from breast, liver,
pancreatic and head and neck cancers," said Martin Keisch, M.D., president and
medical director at Cancer Healthcare Associates in Miami, Florida. "We went
live with our TomoTherapy System in December 2012. We have treated more
than200 patients and our system has not been down for more than one hour. The
TomoTherapy System has redefined how I deliver radiation treatment."

Accuray's newest innovations are the CyberKnife® M6™ Series and the
TomoTherapy® H™ Series Systems treatment solutions. Between them the entire
spectrum of radiation therapy needs are covered. The CyberKnife M6 Series
offers the ability to deliver high-quality, high-dose distributions that can
be confidently delivered to the patient with extreme accuracy over a minimum
number of treatments, reducing side effects and preserving patients' quality
of life. The TomoTherapy H Series facilitates interactive treatment planning
for clinicians to make development of customized plans for a wide range of
patients and disease types efficient. The innovative design of the System
allows treatment plans to be delivered with integrated, daily CT image
guidance, enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue and
critical structures.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells precise, innovative tumor treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range
of radiation therapy and radiosurgery treatments. For more information, please

Safe Harbor Statement

Statements made in this press release that are not statements of historical
fact are forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are not limited
to adoption of new technologies, number of patients treated, clinical
experience, clinical applications, clinical results, and the Company's
leadership position in radiation oncology innovation. Forward-looking
statements are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including risks detailed from
time to time under the heading "Risk Factors" in the company's report on Form
10-K filed on August 29, 2013, and as updated periodically by our other
filings. Forward-looking statements speak only as of the date the statements
are made and are based on information available to the Company at the time
those statements are made and/or management's good faith belief as of that
time with respect to future events. The Company assumes no obligation to
update forward-looking statements to reflect actual performance or results,
changes in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking

SOURCE Accuray Incorporated

Website: http://www.accuray.com
Contact: Rebecca Phillips, Public Relations Manager, Accuray, +1 (408)
716-4773, rphillips@accuray.com; Sherry Feldberg, Schwartz MSL, +1 (781)
684-0770, Accuray@schwartzmsl.com
Press spacebar to pause and continue. Press esc to stop.